• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

    10/24/24 4:06:57 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    SC 13D/A 1 d901674dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Amendment No. 1)*

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2(a)

    Under the Securities Exchange Act of 1934

     

     

    Dynavax Technologies Corporation

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    268158201

    (CUSIP Number)

    David Kroin

    Deep Track Capital, LP

    200 Greenwich Ave, 3rd Floor

    Greenwich, CT 06830

    (203) 409-0810

    with a copy to

    Richard M. Brand

    Daniel P. Raglan

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    (212) 504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 22, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     1.    

     Names of Reporting Persons

     

     Deep Track Biotechnology Master Fund, Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     17,791,486

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     17,791,486

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     17,791,486

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     13.6%*

    14.  

     Type of Reporting Person (See Instructions)

     

     OO

     

    *

    All percentage calculations set forth herein are based upon the aggregate of 131,044,383 shares of Common Stock (as defined below) outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 6, 2024.


     1.    

     Names of Reporting Persons

     

     Deep Track Capital, LP

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     17,791,486

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     17,791,486

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     17,791,486

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     13.6%*

    14.  

     Type of Reporting Person (See Instructions)

     

     IA

     

    *

    All percentage calculations set forth herein are based upon the aggregate of 131,044,383 shares of Common Stock (as defined below) outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 6, 2024.


     1.    

     Names of Reporting Persons

     

     David Kroin

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     17,791,486

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     17,791,486

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     17,791,486

    12.  

     Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     13.6%*

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    *

    All percentage calculations set forth herein are based upon the aggregate of 131,044,383 shares of Common Stock (as defined below) outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 6, 2024.


    This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on September 16, 2024 (the “Schedule 13D”) relating to the common stock, par value $0.001 per share (the “Common Stock”), of Dynavax Technologies Corporation, a Delaware corporation (the “Issuer”). Capitalized terms used in this Amendment No. 1 but not otherwise defined shall have the respective meanings ascribed to them in the Schedule 13D.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    “All of the shares of Common Stock reported herein were purchased by the Reporting Persons for an aggregate investment cost of $201,921,679.34 (including commissions and other fees). The source of funds used by the Reporting Persons to purchase such shares of Common Stock was derived from the capital of DTBMF.

    Unless noted above, no part of the purchase price for such Common Stock was borrowed by any Reporting Person for the purpose of acquiring, holding, trading or voting any securities discussed in this Item 3.”

     

    Item 5.

    Interest in Securities of the Issuer.

    Items 5(a) and (b) of the Schedule 13D are hereby amended and restated in their entirety to read as follows:

    “(a), (b) The Reporting Persons each beneficially owns an aggregate of 17,791,486 shares of Common Stock (the “Subject Shares”). The Subject Shares represent approximately 13.6% of the outstanding shares of Common Stock, based on 131,044,383 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 6, 2024.

    Each of the Reporting Persons may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares.”

    Item 5(c) of the Schedule 13D is hereby amended and supplemented to add the following information:

    “All transactions in the Common Stock effected by the Reporting Persons since September 16, 2024 are set forth on Exhibit 99.3 hereto and that information is incorporated by reference herein.”

     

    Item 7.

    Material to be Filed as Exhibits.

     

    Exhibit 99.3

    Trading Data.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 24, 2024     DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD.
        By:  

    /s/ David Kroin

          Name: David Kroin, Director
    Date: October 24, 2024     DEEP TRACK CAPITAL, LP
        By:  

    /s/ David Kroin

          Name: David Kroin, Managing Member of the General Partner of
       Deep Track Capital, LP
    Date: October 24, 2024     DAVID KROIN
        By:  

    /s/ David Kroin

          David Kroin
    Get the next $DVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

      EMERYVILLE, Calif., June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), Dynavax stockholders have voted to elect all four of its director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – to the Company's Board of Directors. Dynavax issued the following statement:

      6/11/25 11:01:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

      Deep Track's Nominees Are Prepared to Collectively Enter the Boardroom with Open-Minded Perspectives, Constructive Approach and Sole Focus on Creating Value for All Shareholders Believes that Without Meaningful Board Change "Valid and Critical Questions Regarding Dynavax's Strategic Direction, Capital Allocation, and Board Responsiveness" Will Remain Unanswered Details Urgent Need to Address Company's Consistent Failure to Achieve Stated Targets and Reverse Heplisav Market Share Stagnation Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"),

      6/9/25 8:30:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

      Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote "FOR" All Four of Dynavax's Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., June 9, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote "FOR" all four of Dynavax's highly qualified directors standing for e

      6/9/25 7:30:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Silvernail Lauren P was granted 1,439 shares, increasing direct ownership by 17% to 10,075 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:55:43 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kisner Daniel L was granted 5,758 shares, increasing direct ownership by 33% to 23,329 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:53:29 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Myers Scott Dunseth was granted 5,758 shares, increasing direct ownership by 23% to 31,204 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:51:37 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    SEC Filings

    See more
    • Dynavax Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

      8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/17/25 7:30:35 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/9/25 7:44:29 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/6/25 6:04:24 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Leadership Updates

    Live Leadership Updates

    See more
    • Deep Track Capital Comments on ISS Recommendation

      Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

      5/23/25 6:12:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

      ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

      5/23/25 1:44:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • /C O R R E C T I O N -- Dynavax Technologies/

      In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum, issued 07-May-2025 by Dynavax Technologies over PR Newswire, we are advised by the company that the second paragraph, second sentence of the stockholder letter should read "Dynavax has generated over $900 million of stockholder value, returning over 62% versus the S&P Biotechnology Select Industry Index's return of -7%[2]." rather than "Dynavax has generated approximately $1 billion of stockholder value, returning over 104% versus the S&P Biotechnology Select Industry Index's return of only 14%[2]." as originally issued inadvertently. The complete, corre

      5/7/25 4:45:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dynavax downgraded by Goldman with a new price target

      Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

      2/11/25 7:05:05 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Dynavax with a new price target

      Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

      2/1/24 6:20:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Dynavax with a new price target

      JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

      9/27/22 7:39:04 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Financials

    Live finance-specific insights

    See more
    • Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

      Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., May 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.

      5/6/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

      EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav

      4/22/25 4:00:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

      HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2024.

      2/20/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Dynavax Technologies Corporation

      SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      11/14/24 12:18:08 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

      SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/24/24 4:06:57 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

      SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/16/24 9:37:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care